SG11202001460TA - Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt - Google Patents
Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable saltInfo
- Publication number
- SG11202001460TA SG11202001460TA SG11202001460TA SG11202001460TA SG11202001460TA SG 11202001460T A SG11202001460T A SG 11202001460TA SG 11202001460T A SG11202001460T A SG 11202001460TA SG 11202001460T A SG11202001460T A SG 11202001460TA SG 11202001460T A SG11202001460T A SG 11202001460TA
- Authority
- SG
- Singapore
- Prior art keywords
- telmisartan
- formulation
- pharmaceutically acceptable
- acceptable salt
- dissolution rate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170152226A KR102066832B1 (ko) | 2017-11-15 | 2017-11-15 | 텔미사르탄 또는 그의 약제학적으로 허용가능한 염을 포함하는 인습성 및 용출률이 향상된 제제 |
PCT/KR2018/012191 WO2019098540A1 (en) | 2017-11-15 | 2018-10-16 | Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202001460TA true SG11202001460TA (en) | 2020-03-30 |
Family
ID=66539176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202001460TA SG11202001460TA (en) | 2017-11-15 | 2018-10-16 | Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt |
Country Status (6)
Country | Link |
---|---|
KR (1) | KR102066832B1 (ko) |
MY (1) | MY196892A (ko) |
PH (1) | PH12020550597A1 (ko) |
SG (1) | SG11202001460TA (ko) |
TW (2) | TWI734046B (ko) |
WO (1) | WO2019098540A1 (ko) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101010325B1 (ko) * | 2009-12-17 | 2011-01-25 | 현대약품 주식회사 | 텔미사르탄 및 히드로클로로티아지드를 함유하는 약제학적 조성물 |
WO2011149438A1 (en) * | 2010-05-28 | 2011-12-01 | Mahmut Bilgic | Combination of antihypertensive agents |
KR20150111686A (ko) * | 2014-03-26 | 2015-10-06 | 주식회사 종근당 | 산화안정성이 향상된 텔미사르탄 및 (s)-암로디핀을 포함하는 약제학적 제제 |
KR101750689B1 (ko) | 2015-09-15 | 2017-06-26 | 주식회사 종근당 | 약제학적 복합제제 |
KR101823071B1 (ko) * | 2016-02-15 | 2018-01-29 | 한림제약(주) | 텔미사르탄-함유 정제의 제조방법 |
-
2017
- 2017-11-15 KR KR1020170152226A patent/KR102066832B1/ko active IP Right Grant
-
2018
- 2018-10-16 WO PCT/KR2018/012191 patent/WO2019098540A1/en active Application Filing
- 2018-10-16 SG SG11202001460TA patent/SG11202001460TA/en unknown
- 2018-10-16 MY MYPI2020001765A patent/MY196892A/en unknown
- 2018-11-08 TW TW107139601A patent/TWI734046B/zh active
- 2018-11-08 TW TW109108987A patent/TW202026000A/zh unknown
-
2020
- 2020-04-30 PH PH12020550597A patent/PH12020550597A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PH12020550597A1 (en) | 2021-02-15 |
KR102066832B1 (ko) | 2020-01-16 |
WO2019098540A1 (en) | 2019-05-23 |
TW202026000A (zh) | 2020-07-16 |
KR20190055471A (ko) | 2019-05-23 |
TW201922242A (zh) | 2019-06-16 |
TWI734046B (zh) | 2021-07-21 |
MY196892A (en) | 2023-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201906451B (en) | 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same | |
IL257481B (en) | Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof | |
HK1249103B (zh) | 多環氨甲醯基吡啶酮化合物及其藥物用途 | |
IL255823A (en) | Urea derivative or pharmacologically acceptable salt thereof | |
HK1256674A1 (zh) | 氘修飾的brigatinib衍生物、含有該化合物的藥物組合物及其用途 | |
IL273339A (en) | Griseofulbin compound and its medical use | |
IL256339A (en) | Result of pyrazole or its pharmacy salt | |
EP2987786A4 (en) | AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE | |
IL269884B1 (en) | Gamkaban its accepted pharmaceutical salts, their compositions and methods of their use | |
ZA201704743B (en) | Mangiferin-6-o-berberine salt and preparation method and use thereof | |
PL3658122T3 (pl) | Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan | |
IL280389A (en) | Bile acid receptor modulators conjugated to G.1 protein and methods of using them | |
IL250713B (en) | The composition of a pesticide that contains an active ingredient that is soluble in water and increases its penetration and use | |
IL271673A (en) | Preparations containing drugs with increased solubility | |
PL3349594T3 (pl) | Kompozycja zastępująca sól i jej zastosowanie | |
HUE056301T2 (hu) | Szubsztituált karbamidszármazék és annak gyógyászatban történõ alkalmazása | |
HK1243351A1 (zh) | 一種含有吡啶並嘧啶類衍生物或其可藥用鹽的藥物組合物 | |
IL254711B (en) | History of diazepine-indole and medicinal preparations containing them | |
SG11202001460TA (en) | Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt | |
ZA202000959B (en) | Adamantylmethylamine derivative and use thereof as pharmaceutical | |
LT3778609T (lt) | Penamo dariniai arba jo druskos, farmacinės kompozicijos ir jų naudojimas | |
EP3604291A4 (en) | COMPOUND OR SALT THEREOF, ANTIVIRAL AGENT AND PHARMACEUTICAL COMPOSITION | |
AP2017009706A0 (en) | Pharmaceutical compound comprising 13 glycerides, formulation and application thereof | |
PL3072529T3 (pl) | Kompozycja zawierająca wemurafenib i HPMC-AS | |
EP3601246C0 (en) | 16-METHYL-OXACYCLOHEXADECAN-2-ONE AND 16-METHYL-AZACYCLOHEXADECAN-2-ONE DERIVATIVES AS ANTIMICROBIAL AGENTS |